Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Miller J, Puravath A, Orbai AM (2021) Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and patient selection. J Inflamm Res 14:6975–6991
2. Strober B, Leonardi C, Papp KA et al (2017) Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol 76:432–440e17
3. Eli Lilly and Company (2024) Taltz (Ixekizumab) Injection, for Subcutaneous Use (Package Insert). Indianapolis, IN: Eli Lilly and Company. https://pi.lilly.com/us/taltz-uspi.pdf. Accessed 8 May 2024
4. Combe B, Rahman P, Kameda H et al Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis (2020). Arthritis Res Ther. 22:14. https://doi.org/10.1186/s13075-020-2099-0
5. Langhoff E, Olgaard K, Ladefoged J et al (1987) The immunosuppressive potency in vitro of physiological and synthetic steriods on lymphocyte cultures. Int J Immunopharmac 9(4):469–473